



Skin Cancer Detection, Simplified.

- **First** automated skin cancer device for Primary Care Physicians (PCPs)
- **First** automated device indicated for all three common skin cancers (Melanoma, BCC, and SCC)
- **Non-invasive and immediate test results** at the point of care using Elastic Scattering Spectroscopy (ESS) and Artificial Intelligence (AI)
- DermaSensor can be used on **all skin tones**



Better decisions, better detection, more accurate management

DermaSensor empowers physicians by providing objective, actionable risk results to aid in skin cancer detection by assessing cellular and sub-cellular features that cannot be seen visually or dermoscopically.

Features

- Handheld, portable design
- Non-invasive optical spectroscopy
- Beneath the skin, cellular-level analysis
- Immediate objective results
- AI-powered, ultra-miniaturized ESS technology



Indications for use

The DermaSensor™ device is indicated for evaluating skin lesions suggestive of melanoma, basal cell carcinoma, and/or squamous cell carcinoma in patients aged 40 and above, to assist in the decision to refer the patient to a dermatologist. The DermaSensor device should be used in conjunction with the totality of clinically relevant information from the clinical assessment, including visual analysis of the lesion, by physicians who are not dermatologists. The device should be used on lesions already assessed as suspicious for skin cancer and not as a screening tool. The device should not be used as the sole diagnostic criterion nor to confirm clinical diagnosis of skin cancer.






An automated, AI-powered lesion assessment in seconds

AI-powered spectroscopy technology

Xenon lamp pulses light to take ~1mm³ optical tissue samples of cellular features.




Five spectral recordings

The device analyses spectral data across 47 wavelengths for malignancy risk.



Algorithmic analysis

The 0-10 output corresponded to a cancer likelihood of 3% (0) to 61% (10)¹.



Objective, probabilistic output



Clinically proven and validated in real-world practice

- 96% device sensitivity for detecting all skin cancers across Fitzpatrick skin types²
- PCPs correctly referred 91.4% of malignant lesions when aided by the device, compared to just 82.0% without it — a 52% reduction in missed cancer referrals (from 18.0% to 8.6%)³
- Reduce unnecessary referrals — can avoid 21-33%^{1,2} of benign lesions that physicians biopsied and 61-77% of benign lesions of concern to patients, saving patients from expensive dermatology visits^{1,4}
- 91.5% of the study physicians agreed the device added value to their clinical care⁵
- 75% agreed it would help detect more skin cancers⁵
- 71% reported increased confidence in evaluating skin lesions^{5,6}



Featured in Nature's npj | digital medicine

"Learnings from the First AI-Enabled Skin Cancer Device for Primary Care Authorized by the FDA."


* PATIENT-SELECT was a screening-like study design evaluating patient-selected (rather than physician-selected) lesions and powered only for specificity. Device specificity was 61% (77% for pigmented lesions) identified by patients as concerning for skin cancer.



Prioritize what matters — high-risk lesions for timely referrals

DermaSensor provides an immediate, objective result for cancer risk


POSITIVE RESULT



A positive result of “Investigate Further”

is accompanied by a 1-10 spectral score indicating the degree of similarity to malignant lesions; likelihood of cancer ranged from 6% for 1 to 61% for 10¹.

NEGATIVE RESULT



A negative result of “Monitor”

is not accompanied by a 1-10 score given the device’s high sensitivity and negative predictive value; NPV was 97% so only a 3% chance of being cancerous¹.

References:

¹ Merry SP, Croghan IT, Dukes KA, et al. Primary Care Physician Use of Elastic Scattering Spectroscopy on Skin Lesions Suggestive of Skin Cancer. Journal of Primary Care & Community Health. 2025;16. doi:10.1177/21501319251344423

² Seiverling EV, et al. Clinical Utility of an Elastic Scattering Spectroscopy Device in Assisting Primary Care Physicians’ Detection of Skin Cancers. Poster Presentation, Maui Derm Hawaii Conference, Wailea, HI, January 24-28, 2023.

³ Ferris LK, Jaklitsch E, Seiverling EV, et al. DERM-SUCCESS FDA Pivotal Study: A Multi-Reader Multi-Case Evaluation of Primary Care Physicians’ Skin Cancer Detection Using AI-Enabled Elastic Scattering Spectroscopy. J Prim Care Community Health. 2025;16:21501319251342106. doi:10.1177/21501319251342106

⁴ Hartman RI et al., JAAD International (2023), doi: 10.1016/j.jdin.2023.10.0.

⁵ Seiverling, E.V. (2025). JCAD MRMC Study. Journal of Clinical and Aesthetic Dermatology, October 2025, 58–65. Link

⁶ Jaklitsch, E., Chang, S., Bruno, S., D’Angelo, N., Tung, J.K., Ferris, L.K. (2025). Prospective evaluation of an AI-enabled ESS device for triage of patient-identified skin lesions in dermatology clinics. JAAD International, Dec 2025. Mendeley Supplementary Data



Complete solution set to power your practice

DermaSensor patient education resource center

A user-friendly portal that enables customizable patient education materials tailored to your practice

Physician finder

Helps elevate your practice: unlock new patient opportunities by joining the physician finder

E-learning courses

Free access to courses for you and your employees

Remote device monitoring

Device functionality can be assessed remotely by our support team



On-demand customer support

If you have any questions regarding DermaSensor, our support team is here to help

Accessories included

Charging dock, power supply, and regional power adapter blades

Cloud storage access

Customers can access all of their device usage logs and results

One-click updates

Software updates directly to your DermaSensor

Comprehensive device coverage included

If your DermaSensor device malfunctions, our team will troubleshoot, repair, or replace it at no additional cost

The only FDA Breakthrough skin cancer detection device designed for PCPs

TABLE 1: Unlisted CPT code options to consider for DermaSensor™ services

CPT CODE	DESCRIPTOR	APC	APC PAYMENT*	RW**
96999	Unlisted special dermatological service or procedure	5051	\$204.98	2.2423

Disclaimer – The coding and reimbursement information provided in this document is derived from the American Medical Association's Current Procedural Technology (CPT) as well as the Centers for Medicare and Medicaid Services' (CMS) website and copyrighted code sets, 2026. All ICD-10-CM, ICD-10-PCS, CPT, and HCPCS codes referenced herein are for informational purposes only. It is the responsibility of the rendering provider to determine and report appropriate codes, modifiers, and charges for health care services rendered to patients in their care. DermaSensor cannot promise or guarantee that a provider's selection of the codes identified herein are appropriate for a particular procedure or will result in reimbursement from any third-party payer. Questions related to specific coding and coverage policies should be directed to the applicable third-party payer.

The Current Procedural Terminology (CPT) code set is a medical code set copyrighted and maintained by the American Medical Association (AMA) through the CPT Editorial Panel.

The information in this table is an abstract of over 200 Unlisted procedural CPT codes and is provided as a reference in this Guide. Refer to the list of over 200 Unlisted procedural CPT codes for alternative codes that may be deemed more appropriate.

Refer to the Coding Guide for additional information on coding and reimbursement for the DermaSensor procedure.

*The APC Payment amount in Table 1 is for the Outpatient Prospective Payment System (OPPS). Providers billing under site of service 11 are not paid under the OPPS. Payment will be determined by the Medicare contractor or pursuant to payer contract.

** (RW): Relative Weight

TABLE 2: Observed payment amounts on paid claims — historical experience only

CPT CODE	PAYER TYPE	AVERAGE PAYMENT*	MINIMUM PAYMENT*	MAXIMUM PAYMENT*
96999	Commercial	\$128.06	\$60.00	\$396.00
96999	Medicare Advantage	\$164.20	\$100.00	\$198.00
96999	Medicare	\$172.25	\$139.00	\$250.00
96999	Medicaid	\$54.56	\$22.00	\$80.00

These amounts reflect historical paid claims and do not guarantee or predict coverage or reimbursement for future claims.

*The average, minimum, and maximum payment amounts shown above reflect paid claims and are based on historical claims data collected from DermaSensor users between January 1, 2026 and July 20, 2026. These historical payment amounts are provided for informational purposes only and do not represent a fee schedule or guarantee that any claim will be covered or paid. Coverage and payment vary by payer, plan, provider contract, coding, documentation and the circumstances of the particular claim.

DermaSensor Inc. is a medical device company that enables healthcare professionals to effectively check for skin cancer by leveraging cutting-edge technologies. The DermaSensor™ device is a cost-effective handheld tool that uses artificial intelligence and spectroscopy to non-invasively test skin lesions for skin cancer risk in seconds. By enabling quick and effective skin cancer checks, DermaSensor ultimately hopes to improve skin cancer detection and save lives. DermaSensor is currently FDA Cleared, and is available for sale in the U.S.



DermaSensor

Contact us

1.855.373.6767 | [DermaSensor.com](https://www.DermaSensor.com)